From:  Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with axial spondyloarthritis: a 12-month observational study

Remission/low disease activity frequency in axSpA patients at baseline and 6 and 12 months post-switch from originator adalimumab to adalimumab-AACF

Remission/low disease activity frequency at baseline and after switching (n = 28)Baseline6 monthsP12 monthsP
ASDAS-CRP < 2.120 (71.4%)22 (78.6%)0.61722 (78.6%)0.683
Return to article view

Data are presented as number (%); statistical significance was considered when P < 0.05. ASDAS-CRP: Ankylosing Spondylitis Disease Activity Score-C-reactive protein